| ALK gene rearrangement |
View Test |
| BCR-ABL1 t(9;22)(q34;q11) Diagnostic (for suspected CML) |
View Test |
| BCR-ABL1 t(9;22)(q34;q11) E1A2, E13A2 & E14A2 transcripts Diagnostic Acute Leukaemia |
View Test |
| BRAF mutation analysis |
View Test |
| CBFB-MYH11 inv(16) / t(16;16) Diagnostic (AML) |
View Test |
| DPYD Genotyping |
View Test |
| EGFR mutation analysis (blood) |
View Test |
| EGFR mutation analysis (FFPE) |
View Test |
| ETV6-RUNX1 t(12;21)(p13;q22) Diagnostic (ALL) |
View Test |
| FIP1L1-PDGFRA fusion gene |
View Test |
| FLT3 |
View Test |
| FOXL2 mutation analysis |
View Test |
| HER2 gene amplification |
View Test |
| IDH1 and IDH2 mutation analysis |
View Test |
| Immunoglobulin HV Gene Sequencing |
View Test |
| KIT and PDGFRA mutation analysis |
View Test |
| KIT D816V Mutation Testing |
View Test |
| KMT2A (MLL, 11q23) rearrangement Diagnostic test for Acute Leukaemia |
View Test |
| KRAS mutation analysis |
View Test |
| MGMT promoter methylation analysis |
View Test |
| Mismatch repair testing |
View Test |
| MRD monitoring for BCR-ABL1 E13A2 and/or E14A2 transcripts |
View Test |
| MRD monitoring for BCR-ABL1 E1A2 transcript |
View Test |
| Next Generation Sequencing (NGS) for Myeloid Disorders |
View Test |
| NPM1 |
View Test |
| NRAS mutation analysis |
View Test |
| PD-L1 immunohistochemistry |
View Test |
| PML-RARA t(15;17)(q22;q21) Diagnostic (AML) |
View Test |
| ROS1 gene rearrangement |
View Test |
| RUNX1-RUNX1T1 t(8:21)(q22;q22) Diagnostic (AML) |
View Test |
| TCF3-PBX1 t(1;19)(q23;p13) Diagnostic (ALL) |
View Test |
| TCR Gene Clonality |
View Test |
| TP53 |
View Test |
